CuraGen Announces Expansion Of CR011-vcMMAE Phase II Trial In Melanoma
CuraGen Corporation (Nasdaq: CRGN), a clinical-stage biopharmaceutical company focused on oncology, announced that its Phase II Trial evaluating CR011-vcMMAE for the treatment of patients with unresectable Stage III or Stage IV melanoma has met the efficacy criteria for advancement to the second stage of enrollment.
Cloned Immune Cells Treat Skin Cancer
"A cancer patient has made a full recovery after being injected with billions of his own immune cells in the first case of its kind, " The Daily Telegraph reported. The newspaper described how a 52-year-old man with advanced melanoma, a type of skin cancer that usually has a poor prognosis once it has spread, has made a full recovery.
As Summer Heats Up, New Survey Reveals Need For Effective Sweat Treatments
As the thermometer rises, so does the humidity. For many, the humidity can be annoying, but for the nearly 8 million Americans who suffer from a treatable condition called hyperhidrosis(1), or excessive sweating, the humidity can be unbearable. Hyperhidrosis affects underarms, palms, feet and head, among other areas, and though not caused by heat, is aggravated by heat or anxiety.
More Research Needed To Understand Scleroderma
With an estimated 14 million cases worldwide, you would think more would be known about scleroderma, a chronic, debilitating disease that can lead to the hardening and tightening of skin and connective tissue. But it seems that we don't know enough: "We don't have all the answers and that is the reason why we need to do more research, " says Carol Feghali-Bostwik, Ph.
Senesco Expands On Preclinical Multiple Myeloma Findings
Senesco Technologies, Inc. ("Senesco" or the "Company") (Amex: SNT) announced further details of its continuing preclinical multiple myeloma research. In February 2008, the Company announced results of preclinical animal studies in which Senesco's Factor 5A technology, encapsulated in nanoparticles, was able to induce apoptosis in multiple myeloma tumors when injected intratumorally.
Dermatologists Report Increased Use Of Biologics In The Treatment Of Psoriasis
BioTrends Research Group, Inc. released its third annual TreatmentTrends (TM): Psoriasis publication, providing insight into the management of psoriasis. This report is based on responses to an online survey completed by 102 US Dermatologists in April 2008.
Study Supports Possible Use Of Leukine R As A Potential Adjuvant Therapy For High-Risk Melanoma Patients
Results from an adjuvant trial in high-risk melanoma patients demonstrated that a majority of patients treated with Leukine(R) (sargramostim) achieved disease-free and/or overall survival. These findings, which indicate Leukine's potential in this cancer setting, were released at the 44th annual meeting of the American Society of Clinical Oncology (ASCO).
Another New Wrinkle In Treating Skin Aging
Topical applications of a naturally occurring fat molecule have the potential to slow down skin aging, whether through natural causes or damage, researchers report.Through both the normal aging process and external factors like UV damage, smooth, young skin inevitably becomes coarse and wrinkled.
Restless Leg Syndrome Relief Found In Rotigotine Skin Patch
Patients with restless leg syndrome (RLS) - the irresistible urge tomove one's body to limit uncomfortable or odd sensations - may get somerelief during day and night by using skin patches that contain the drugrotigotine. The findings come from a randomized, placebo-controlled, double-blind study published in the July edition of TheLancet Neurology.
Malignant Melanoma Classification Given Additional Genetic Component
Existing melanoma classifications have been refined by a team at theUniversity of California San Francisco according to an article releasedon June 2, 2008 in the open access journal PLoS Medicine.Melanoma, a malignant tumor of melanocytes, are presently classified bymorphological means.